Compare · DXCM vs IRTC
DXCM vs IRTC
Side-by-side comparison of DexCom Inc. (DXCM) and iRhythm Holdings Inc. (IRTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and IRTC operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.65B, about 8.3x IRTC ($4.06B).
- IRTC has been more active in the news (13 items in the past 4 weeks vs 9 for DXCM).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- iRhythm Holdings Inc.
- Price
- -
- -
- Market cap
- $33.65B
- $4.06B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2016
- News (4w)
- 9
- 13
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
iRhythm Holdings Inc.
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.
Latest IRTC
- iRhythm Holdings Inc. filed SEC Form 8-K: Leadership Update
- President and CEO Blackford Quentin S. was granted 48,534 shares and sold $3,348,012 worth of shares (26,859 units at $124.65), increasing direct ownership by 11% to 226,008 units (SEC Form 4) (for withholding tax)
- CBO and CLO Murphy Patrick Michael was granted 13,589 shares and sold $884,156 worth of shares (7,093 units at $124.65), increasing direct ownership by 10% to 69,699 units (SEC Form 4) to satisfy withholding tax
- EVP, Chief Risk Officer Shrishrimal Sumi was granted 9,706 shares and sold $669,641 worth of shares (5,372 units at $124.65), increasing direct ownership by 11% to 44,621 units (SEC Form 4) (withholding tax)
- CHIEF COMM & PRODUCT OFFICER Patterson Chad was granted 13,589 shares and sold $884,170 worth of shares (7,093 units at $124.65), increasing direct ownership by 12% to 62,125 units (SEC Form 4) (for withholding tax)
- CHIEF MED/SCI OFCR EVP ADVTECH Turakhia Minang sold $884,151 worth of shares (7,093 units at $124.65) and was granted 13,589 shares, increasing direct ownership by 12% to 60,116 units (SEC Form 4) to satisfy tax liability
- SEC Form 10-Q filed by iRhythm Holdings Inc.
- iRhythm Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- iRhythm Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- iRhythm to Acquire VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care